Elsevier

Neuroscience

Volume 63, Issue 3, December 1994, Pages 637-652
Neuroscience

Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains

https://doi.org/10.1016/0306-4522(94)90511-8Get rights and content

Abstract

The distribution and density of cannabinoid receptor binding and messenger RNA expression in aged human brain were examined in several forebrain and basal ganglia structures. In vitro binding of [3H]CP-55,940, a synthetic cannabinoid, was examined by autoradiography in fresh frozen brain sections from normal aged humans (n = 3), patients who died with Alzheimer's disease (n = 5) and patients who died with other forms of cortical pathology (n = 5). In the structures examined—hippocampal formation, neocortex, basal ganglia and parts of the brainstem—receptor binding showed a characteristic pattern of high densities in the dentate gyrus molecular layer, globus pallidus and substantia nigra pars reticulata, moderate densities in the hippocampus, neocortex, amygdala and striatum, and low densities in the white matter and brainstem. In situ hybridization histochemistry of human cannabinoid receptor, a ribonucleotide probe for the human cannabinoid receptor messenger RNA, showed a pattern of extremely dense transcript levels in subpopulations of cells in the hippocampus and cortex, moderate levels in hippocampal pyramidal neurons and neurons of the striatum, amygdala and hypothalamus, and no signal over dentate gyrus granule cells and most of the cells of the thalamus and upper brainstem, including the substantia nigra. In Alzheimer's brains, compared to normal brains, [3H]CP-55,940 binding was reduced by 37–45% in all of the subfields of the hippocampal formation and by 49% in the caudate. Lesser reductions (20–24%) occurred in the substantia nigra and globus pallidus, internal segment. Other neocortical and basal ganglia structures were not different from control levels. Levels of messenger RNA expression did not differ between Alzheimer's and control brains, but there were regionally discrete statistically significant losses of the intensely expressing cells in the hippocampus. The reductions in binding did not correlate with or localize to areas showing histopathology, estimated either on the basis of overall tissue quality or silver staining of neuritic plaques and neurofibrillary tangles.

Reduced [3H]CP-55,940 binding was associated with increasing age and with other forms of cortical pathology, suggesting that receptor losses are related to the generalized aging and/or disease process and are not selectively associated with the pathology characteristic of Alzheimer's disease, nor with overall decrements in levels of cannabinoid receptor gene expression.

Reference (51)

  • MailleuxP. et al.

    Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides

    Neurosci. Lett.

    (1992)
  • MailleuxP. et al.

    Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry

    Neuroscience

    (1992)
  • McDonaldW.M. et al.

    Neurotransmitters and neuropeptides in Alzheimer's disease

    Psychiat. Clin. N. Am.

    (1991)
  • MillerL.L.

    Marijuana: acute effects on human memory

  • ProbstA. et al.

    Differential modification of muscarinic cholinergic receptors in the hippocampus of patients with Alzheimer's disease: an autoradiographic study

    Brain Res.

    (1988)
  • AlheidG.E. et al.

    Basal ganglia

  • AllardP. et al.

    Loss of dopamine uptake sites labeled with [3H]GBR-12935 in Alzheimer's disease

    Eur. Neurol.

    (1990)
  • American Psychiatric Association
  • BlassJ.P. et al.

    Pathology of Alzheimer's disease

    Psychiat. Clin. N. Am.

    (1991)
  • CampbellS.K. et al.

    Alzheimer's plaques and tangles: a controlled and enhanced silver staining method

    Soc. Neurosci. Abstr.

    (1987)
  • CarpenterM.B.

    Interconnections between the corpus striatum and brain stem nuclei

  • DeArmondS.J. et al.

    Structure of the Human Brain: A Photographic Atlas

    (1989)
  • de la MonteS.M.

    Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer's disease

    Ann. Neurol.

    (1989)
  • DewarD. et al.

    5-HT2 receptors in dementia of Alzheimer type: a quantitative autoradiographic study of frontal cortex and hippocampus

    J. neural Transm. Park. Dis. Dement. Sec.

    (1990)
  • DeweyW.L.

    Cannabinoid pharmacology

    Pharmac. Rev.

    (1986)
  • Cited by (239)

    • Cannabinoids and endocannabinoid signaling at the basal forebrain cholinergic system

      2023, Cannabis Use, Neurobiology, Psychology, and Treatment
    • Endocannabinoid system reactivity during stress processing in healthy humans

      2022, Biological Psychology
      Citation Excerpt :

      With regard to the neurobiology of stress, neuroimaging studies in humans have identified several brain regions, which are primarily involved in the processing of stress and emotion regulation, namely the ventromedial prefrontal cortex (vmPFC), the amygdala and the hippocampus (Duval, Javanbakht, & Liberzon, 2015; Etkin, Egner, & Kalisch, 2011; Gramsch et al., 2014). Interestingly, these brain regions are also known to have a high endocannabinoid (eCB) receptor density (Glass et al., 1997; Westlake et al., 1994). Animal research suggests that the endocannabinoid system (ECS) with its two main eCBs anandamide (AEA) and 2-arachidonoylglycerol (2-AG) comes into play at the point of termination of the initial phase of the stress response mediated by the HPA-axis (Gray et al., 2015).

    View all citing articles on Scopus

    Present address: Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC 29425, U.S.A.

    View full text